Oncology Drugs Market, by Drug Type (Cytotoxic Drugs (Alkylating Agents, Antimetabolites, and Others), Targeted Drugs (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, and Others), and Hormonal Drugs (Ovarian Function Blockers, Estrogen Production Blockers, and Estrogen’s Effect Blockers (Selective Estrogen Receptor Modulators (SERMs) and Others)), by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Bladder Cancer, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  • Published On : Dec 2018 |
  • Pages : 188 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Oncology Drugs Market Insights – Cancer can be cured

Cancer is a class of chronic disease that is characterized by uncontrolled growth of cells. The most common cancer types are breast cancer, lung cancer, colorectal cancer, uterine cancer, and thyroid cancer. The three main types of drugs used for cancer, based on their mechanism of action, are cytotoxic drugs, targeted drugs, and hormonal drugs. Oncology drugs market has witnessed tremendous growth in the recent past, owing to increasing drug approvals and emergence of biosimilar products for cancer treatment. Furthermore, increasing healthcare expenditure for cancer has led to growing research and development activities for developing new cancer drugs that are highly effective and with least side-effects.

The global oncology drugs market size is estimated to be valued at US$ 77.3 billion in 2018 and is expected to witness a CAGR of 12.3% over the forecast period (2018 – 2026).

Figure 1. Global Oncology Drugs Market Share, By Region

Source: Coherent Market Insights Analysis (2018)

Increasing preference of immunotherapy for the treatment of cancer is driving the oncology drugs market growth

Key companies in the oncology drugs market are focused on targeting cancer treatment based on personalized medicines. According to Tufts Center for the Study of Drug Development (CSDD), 2015 report, 73% of the cancer medicines in the development have potential to be personalized medicine. Several researches are focused on targeting cancer at molecular level to offer new cancer treatments. According to an article published in The Biopharmaceutical Pipeline, 2013, new molecular entity for cancer treatment holds 80% share in the total pipeline products for cancer treatment. According to same source, the total number of potential first-in-class projects for cancer are 4,358 out of total 5,473 cancer projects.

However, several blockbuster oncology drugs are expected to lose their patent during 2018-2020, which in turn is expected to hamper the market growth during the forecast period. For instance, Roche’s Avastin, which is a humanized monoclonal antibody for the indication of colorectal, lung, breast, glioblastoma, kidney, and ovarian cancer is expected to lose its patent in July 2019 in the U.S. and in January 2022 in Europe. Some of the other drugs that are under patent expiration include, Bristol-Myers Squibb and Eli Lilly and Company’s Erbitux (cetuximab) by 2018; Roche’s Herceptin (trastuzumab) by 2019 and MabThera (Rituximab) by 2018; and Sanofi’s Zaltrap by 2020.

Presence of key market players and increasing drug approvals are attributing to the highest share of North America market in the global oncology drugs market

Regional oncology drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America oncology drugs market holds dominant position in the global oncology drugs market. Advanced medical treatment options available for cancer in economies such as the U.S. and increasing survival rate are key factors driving the market growth. For instance, according to the American Association for Cancer Research’s 2015 report, the number of survivors suffering from cancer increased from 9.8 million in 2001 to 14.5 million in 2014, owing to increasing adoption of better medical facilities. Moreover, increasing R&D activities by local players such as Spark Therapeutics, Inc. and Kite Pharmaceuticals and increasing product approvals by the U.S. FDA are boosting the market growth in North America.

Furthermore, Asia Pacific is expected to witness significant growth in the market, owing to increasing focus of international player on strategies such as mergers and acquisitions. For instance, in February 2018, Merck acquired Viralytics Limited, a Sydney-based immune-oncology drug developer, to strengthen its immune-oncology drug pipeline. Moreover, increasing prevalence of various types of cancer in economies such as India and China is also expected to propel growth of the market. For instance, according to the American Cancer Society, 2015, around 4.3 million new cancer cases and over 2.8 million cancer deaths were recorded in China, with lung cancer being the most common and the leading cause of cancer deaths.


Figure 2. Global Oncology Drugs Market Share, By Region

Source: Coherent Market Insights Analysis (2018)

Market players are focused on mergers with research institutes and acquisition of small market players

Key players in the oncology drugs market are focused on strategies such as mergers with research institutes and acquisition of small market players in order to enhance their market share. This in turn is expected to boost the market growth over the forecast period. For instance, in May 2018, Eli Lilly and Company acquired two market players, Armo BioSciences and AurKa Pharma for US$ 1.6 billion and US$ 111 million, respectively, to expand its cancer portfolio. In March 2016, Kite Pharma, Inc. collaborated with Genentech, a member of Roche Group, to evaluate a drug molecule, KTE-C19 in combination with atezolizumab for refractory, aggressive non-Hodgkin lymphoma (NHL). The trials are conducted under the names ZUMA-1, ZUMA-2, ZUMA-3, and ZUMA-4.

Major players operating in the global oncology drugs market include, Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Eli Lilly and Company, AbbVie, Inc., AstraZeneca plc., Bayer AG, and Amgen Inc.

Group of cells that lose contact inhibition growth mechanism leads to development of tumor, which is potent to grow infinitely at its origin or can invade into blood stream and lead to tumor at different sites. Based on the location ability of tumor cancer, it is classified as benign tumor or malignant tumor, respectively. The global oncology drugs market is segmented by drug type, by cancer type, and by distribution channel. Based on the drug type, the market is segmented into cytotoxic drugs, targeted drugs, and hormonal drug. Targeted drugs specifically target cancerous cells, which helps in reducing the side effects of the drugs. This in turn propels growth of targeted drugs segment.

Market Dynamics

Increasing drug approvals and robust pipeline for novel therapeutic agents are some of the key factors driving the oncology drugs market growth. For instance, in August 2017, Tisagenlecleucel (Kymriah), a drug developed by Novartis was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric and young adults with refractory or relapsed Acute Lymphoblastic Leukemia (ALL). Moreover, increasing prevalence of various types of cancer is also fueling the oncology drugs market growth. For instance, according to a report by National Cancer Institute, 2016, around 16.8 million new cases of cancer are diagnosed in the U.S. every year, with around 595,690 deaths from the disease and the number of people with cancer is expected to increase to 19 million by 2024.

However, high cost of cancer drugs and adoption of alternative treatment options such as surgery and radiation therapy are major factors hindering the oncology drugs market growth. Several blockbuster oncology drugs in the market are expected to lose patent during 2018-2020, which is turn acts as an opportunities for emerging players in the global oncology drugs market.

Key features of the study:

  • This report provides in-depth analysis of the oncology drugs market and its application, market size (US$ Million) and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include, Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Eli Lilly and Company, AbbVie, Inc., AstraZeneca plc., Bayer AG, and Amgen Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion and marketing tactics.
  • The global oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of oncology drug, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the oncology drugs market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Oncology Drugs Market, By Drug Type:
      • Cytotoxic Drugs
        • Alkylating Agents
        • Antimetabolites
        • Others
      • Targeted Drugs
        • Monoclonal Antibodies
        • Tyrosine Kinase Inhibitors
        • Others
      • Hormonal Drugs
        • Ovarian Function Blockers
        • Estrogen Production Blockers
        • Estrogen’s Effect Blockers
          • Selective Estrogen Receptor Modulators (SERMs)
          • Others
  • Global Oncology Drugs Market, By Cancer Type:
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Blood Cancer
    • Bladder Cancer
    • Others
  • Global Oncology Drugs Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Oncology Drugs Market, By Region:
    • North America
      • By Drug Class:
        • Cytotoxic Drugs
          • Alkylating Agents
          • Antimetabolites
          • Others
        • Targeted Drugs
          • Monoclonal Antibodies
          • Tyrosine Kinase Inhibitors
          • Others
        • Hormonal Drugs
          • Ovarian Function Blockers
          • Estrogen Production Blockers
          • Estrogen’s Effect Blockers
            • Selective Estrogen Receptor Modulators (SERMs)
            • Others
      • By Cancer Type:
        • Lung Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Prostate Cancer
        • Blood Cancer
        • Bladder Cancer
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Cytotoxic Drugs
          • Alkylating Agents
          • Antimetabolites
          • Others
        • Targeted Drugs
          • Monoclonal Antibodies
          • Tyrosine Kinase Inhibitors
          • Others
        • Hormonal Drugs
          • Ovarian Function Blockers
          • Estrogen Production Blockers
          • Estrogen’s Effect Blockers
            • Selective Estrogen Receptor Modulators (SERMs)
            • Others
      • By Cancer Type:
        • Lung Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Prostate Cancer
        • Blood Cancer
        • Bladder Cancer
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Cytotoxic Drugs
          • Alkylating Agents
          • Antimetabolites
          • Others
        • Targeted Drugs
          • Monoclonal Antibodies
          • Tyrosine Kinase Inhibitors
          • Others
        • Hormonal Drugs
          • Ovarian Function Blockers
          • Estrogen Production Blockers
          • Estrogen’s Effect Blockers
            • Selective Estrogen Receptor Modulators (SERMs)
            • Others
      • By Cancer Type:
        • Lung Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Prostate Cancer
        • Blood Cancer
        • Bladder Cancer
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Cytotoxic Drugs
          • Alkylating Agents
          • Antimetabolites
          • Others
        • Targeted Drugs
          • Monoclonal Antibodies
          • Tyrosine Kinase Inhibitors
          • Others
        • Hormonal Drugs
          • Ovarian Function Blockers
          • Estrogen Production Blockers
          • Estrogen’s Effect Blockers
            • Selective Estrogen Receptor Modulators (SERMs)
            • Others
      • By Cancer Type:
        • Lung Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Prostate Cancer
        • Blood Cancer
        • Bladder Cancer
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Cytotoxic Drugs
          • Alkylating Agents
          • Antimetabolites
          • Others
        • Targeted Drugs
          • Monoclonal Antibodies
          • Tyrosine Kinase Inhibitors
          • Others
        • Hormonal Drugs
          • Ovarian Function Blockers
          • Estrogen Production Blockers
          • Estrogen’s Effect Blockers
            • Selective Estrogen Receptor Modulators (SERMs)
            • Others
      • By Cancer Type:
        • Lung Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Prostate Cancer
        • Blood Cancer
        • Bladder Cancer
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Cytotoxic Drugs
          • Alkylating Agents
          • Antimetabolites
          • Others
        • Targeted Drugs
          • Monoclonal Antibodies
          • Tyrosine Kinase Inhibitors
          • Others
        • Hormonal Drugs
          • Ovarian Function Blockers
          • Estrogen Production Blockers
          • Estrogen’s Effect Blockers
            • Selective Estrogen Receptor Modulators (SERMs)
            • Others
      • By Cancer Type:
        • Lung Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Prostate Cancer
        • Blood Cancer
        • Bladder Cancer
        • Others
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
      • Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Novartis International AG
      • Celgene Corporation
      • Johnson & Johnson
      • Bristol-Myers Squibb
      • Pfizer Inc.
      • Merck & Co.
      • Eli Lilly and Company
      • AbbVie, Inc.
      • AstraZeneca plc.
      • Bayer AG
      • Amgen Inc.

Strategies “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
    • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Cancer Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Major Brand Analysis
    • Pipeline Analysis
      • By Drug Type
      • By Cancer Type
      • By Clinical Trial Phase
    • Patent Expiry List (2018-2026)
    • Investments for R&D
    • Reimbursement Scenario
    • Mergers & Acquisitions
    • Collaborations
    • Epidemiology
    • PEST Analysis
  4. Global Oncology Drugs Market, By Drug Type, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Cytotoxic Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
        • Alkylating Agents
        • Antimetabolites
        • Others
    •  Targeted Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
        • Monoclonal Antibodies
        • Tyrosine Kinase Inhibitors
        • Others
    • Hormonal Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
        • Ovarian Function Blockers
        • Estrogen Production Blockers
        • Estrogen’s Effect Blockers
  • Selective Estrogen Receptor Modulators (SERMs)
  • Others
  1. Global Oncology Drugs Market, By Cancer Type, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Colorectal Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Prostate Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Blood Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Bladder Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  2. Global Oncology Drugs Market, By Distribution Channel, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  3. Global Oncology Drugs Market, By Region, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Cancer Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • Northern Africa
        • Central Africa
        • South Africa
  4. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Celgene Corporation
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Merck & Co.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • AbbVie, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • AstraZeneca plc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
  1. Analyst Views
  2. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 32 market data tables and 30 figures on “Oncology Drugs Market - Global forecast to 2026”.

 

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.